GlobeNewswire

Ascom announces Ascom Myco 3 smartphone approved for the Target Platform for Epic Rover

Share

Ascom calls listing “yet another exciting step forward” for its flagship healthcare mobile device

BAAR, Switzerland, May 14, 2019 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, has announced that the Ascom Myco 3 smartphone has been listed on the Target Platform for the Epic Rover healthcare application. The app gives clinical users of Epic’s Electronic Health Record access to tools for clinical review, medication administration, specimen collection, and other clinical documentation workflows right from their mobile devices.

Part of the Ascom Healthcare Platform, the Ascom Myco 3 smartphone is available in cellular and Wi-Fi versions. Running on the Android 8.1 OS, the device features a HD 5” touchscreen, an integrated enterprise-grade barcode scanner, NFC functionality and a true hot-swappable battery. It works together with Ascom and third-party software and apps to put context-rich information from multiple sources into the hands of highly mobile clinicians. Designed for clinical and other demanding environments, the Ascom Myco 3 combines a robust yet ergonomic form with advanced integration capabilities and enterprise-grade security features.

For Ascom Chief Sales and Marketing Officer Francis Schmeer, the listing is “yet another exciting step forward for the Ascom Myco 3 smartphone.” The device works with apps such as Rover to connect clinicians to patient data, colleagues and IT systems—helping to streamline workflows, boost productivity and ultimately contribute to enhanced patient satisfaction and outcomes. 

Schmeer also points to the app’s interoperability with the Ascom Myco 3 embedded barcode scanner as an example of how the smartphone enables mobile functionality for clinicians. “The Ascom Myco 3 barcode scanner lets clinicians securely identify patients, medications and colleagues at the point of care and while on the go. It’s a clear illustration of how the smartphone benefits busy clinicians, enabling smooth access to key data, and the ability to communicate and coordinate with colleagues, systems and patients.”

Epic and Rover are registered trademarks of Epic Systems Corporation.

Android is a trademark of Google LLC.

About Ascom

Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere. Ascom’s mission is to provide mission-critical, real-time solutions for highly mobile, ad hoc, and time-sensitive environments. Ascom uses its unique product and solutions portfolio and software architecture capabilities to devise integration and mobilization solutions that provide truly smooth, complete, and efficient workflows for healthcare as well as for industry and retail sectors.

Ascom is headquartered in Baar (Switzerland), has operating businesses in 18 countries and employs around 1,300 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Outotec's research center in Pori: 70 years supporting sustainable growth15.10.2019 08:00:00 CESTPress release

OUTOTEC OYJ PRESS RELEASE OCTOBER 15, 2019 9:00 AM Outotec's research center in Pori: 70 years supporting sustainable growth Outotec Research Center (ORC) in Pori is unique in the industry – its expertise in the minerals and metals processing value chain ranges from ores to finished metals and recycling. The research center was established in 1949, and since then it has been a part of the company's long-term research and development strategy. ORC has developed numerous cutting-edge technologies. For example, Outotec Flash Smelting, which is still is one of the world’s most commonly used processes for the production of primary copper and nickel, was developed in ORC at the end of 1940s. The center's laboratories conduct tests on raw materials for Outotec's customers and the related production processes. Current testing capabilities include nine laboratories and pilot plants. Annually, there are approximately 200 research projects with more than 250,000 samples analyzed. Over the decades

Scanship Holding ASA : Invitation to 3Q2019 Trading update on Tuesday 22 October14.10.2019 21:52:00 CESTPress release

Welcome to Scanship Holding ASA's 3Q2019 Trading update at hrs. 12.00 on Tuesday 22 October in Oslo. With the recent acquisition of ETIA, Scanship has significantly broadened and expanded its adressable market, and the presentation will include more insight to forward growth strategies within the various landbased markets. Special attention will be given on Scanship's value proposition for the European biogas market and within chemical recycling of plastic waste. The presentation will be held at MESH in Tordenskioldsgate 3, and a light lunch will be served. Please notify Scanship by e-mail to attend: erik.magelssen@scanship.no, or cell + 47 928 88 728 Venue: MESH, the Lounge, Tordenskiolds gate 3, 0160 Oslo For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: henrik.badin@scanship.no ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advan

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB14.10.2019 20:48:00 CESTPress release

The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. The registration opens at 13:30 CET. NOTICE OF ATTENDANCE Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Wednesday 30 October 2019 and give notice of intent to participate to the Company no later than on Wednesday 30 October 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18-51 08 73 or by e-mail: info@oasmia.com, and specify the number of advisors (maximum two). If shareholder’s attendance and right at the meeting will be exercised by proxy, we would be grateful if such is provided in connection with the notification of attendance. A proxy form is available to shareholders upon request and is avaliable at the Comp

Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB14.10.2019 20:48:00 CESTPressemelding

Aktieägarna i Oasmia Pharmaceutical AB (”Bolaget”) kallas härmed till extra bolags­stämma onsdagen den 6 november 2019 kl. 14:00, i Bolagets lokaler, Vallongatan 1, 752 28 Uppsala. Inregistrering påbörjas kl. 13:30. ANMÄLAN Aktieägare som önskar delta vid bolagsstämman skall dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 30 oktober 2019, dels anmäla sitt deltagande till Bolaget senast onsdagen den 30 oktober 2019 under adress Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, per fax: 018-51 08 73 eller via e-post: info@oasmia.com, varvid antalet biträden skall anges (högst två). Om deltagande skall ske med stöd av fullmakt är vi tacksamma om sådan ges in redan i samband med anmälan. Fullmakten får inte vara äldre än ett år gammal, dock att fullmakten får vara äldre än ett år om det framgår att den är giltig för en längre period, längst fem år. Fullmaktsformulär tillhandahålls aktieägare på begäran och finns tillgängligt hos Bolaget och på Bolagets we

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million14.10.2019 20:46:00 CESTPress release

The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization of Apealea® and capture new business opportunities based on the Company's proprietary XR17 platform. Moreover, Oasmia intends to create a stable financial position enabling a solid platform for growth. The Company’s major shareholder Per Arwidsson through Arwidsro Investment AB and related parties (“Arwidsro”) has undertaken to subscribe for its pro-rata share in the Rights Issue, corresponding to approximately SEK 100 million or 25 percent. Oasmia has also received a financing commitment from Arwidsro enabling Oasmia to repay the convertible loan on 31 October

Styrelsen i Oasmia föreslår en företrädesemission om cirka 400 MSEK14.10.2019 20:46:00 CESTPressemelding

Styrelsen i Oasmia Pharmaceutical AB (”Oasmia” eller ”Bolaget”) offentliggör idag kallelse till extra bolagsstämma den 6 november 2019. Bolagsstämman föreslås besluta att bemyndiga styrelsen att genomföra en företrädesemission om cirka 400 MSEK (”Företrädesemissionen”). Likviden från Företrädesemissionen ska huvudsakligen användas för att finansiera och accelerera kommersialiseringen av Apealea® samt tillvarata nya affärsmöjligheter baserade på Bolagets egenutvecklade XR17-plattform. Därutöver avser Oasmia att skapa en stabil finansiell position för att möjliggöra framtida tillväxt. Bolagets största aktieägare Per Arwidsson via Arwidsro Investment AB och närstående (”Arwidsro”) har åtagit sig att teckna sig för sin pro rata-andel i Företrädesemissionen, motsvarande cirka 100 MSEK eller 25 procent. Oasmia har också fått ett finansieringsåtagande från Arwidsro som möjliggör för Oasmia att återbetala det utestående konvertibellånet den 31 oktober 2019. Sammanfattning Styrelsen offentliggö